NVAX Novavax Inc

Price (delayed)

$127.43

Market cap

$8.11B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.17

Enterprise value

$8.15B

Sector: Healthcare
Industry: Biotechnology

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III ...

Highlights

Novavax's equity has surged by 156% YoY but it has decreased by 42% QoQ
Novavax's EPS has shrunk by 91% QoQ but it has increased by 27% YoY
Novavax's net income has plunged by 192% from the previous quarter and by 81% YoY
Novavax's debt has increased by 38% YoY and by 37% QoQ

Key stats

What are the main financial stats of NVAX
Market
Shares outstanding
63.66M
Market cap
$8.11B
Enterprise value
$8.15B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
73.36
Price to sales (P/S)
38.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
39.81
Earnings
Revenue
$204.76M
EBIT
-$257.86M
EBITDA
-$253.83M
Free cash flow
$49.46M
Per share
EPS
-$5.17
Free cash flow per share
$0.8
Book value per share
$1.74
Revenue per share
$3.33
TBVPS
$13.19
Balance sheet
Total assets
$944.02M
Total liabilities
$637.76M
Debt
$440.64M
Equity
$106.44M
Working capital
$432M
Liquidity
Debt to equity
4.14
Current ratio
2.81
Quick ratio
2.46
Net debt/EBITDA
-0.15
Margins
EBITDA margin
-124%
Gross margin
100%
Net margin
-133.1%
Operating margin
-128.2%
Efficiency
Return on assets
-45.9%
Return on equity
-1,346.2%
Return on invested capital
-60.2%
Return on capital employed
-36.6%
Return on sales
-125.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVAX stock price

How has the Novavax stock price performed over time
Intraday
-1.96%
1 week
4.57%
1 month
0.96%
1 year
2,809.36%
YTD
14.28%
QTD
14.28%

Financial performance

How have Novavax's revenue and profit performed over time
Revenue
$204.76M
Gross profit
$204.76M
Operating income
-$262.57M
Net income
-$272.53M
Gross margin
100%
Net margin
-133.1%
Novavax's net income has plunged by 192% from the previous quarter and by 81% YoY
Novavax's operating income has plunged by 90% YoY
Novavax's net margin has surged by 86% YoY and by 28% QoQ
The operating margin has soared by 85% year-on-year and by 23% since the previous quarter

Growth

What is Novavax's growth rate over time

Valuation

What is Novavax stock price valuation
P/E
N/A
P/B
73.36
P/S
38.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
39.81
Novavax's EPS has shrunk by 91% QoQ but it has increased by 27% YoY
Novavax's equity has surged by 156% YoY but it has decreased by 42% QoQ
NVAX's P/S is 37% above its 5-year quarterly average of 27.9 but 9% below its last 4 quarters average of 42.1

Efficiency

How efficient is Novavax business performance
The ROIC has plunged by 171% from the previous quarter and by 49% YoY
NVAX's return on assets has dropped by 97% since the previous quarter but it is up by 40% year-on-year
Novavax's return on sales has surged by 85% YoY and by 21% QoQ

Dividends

What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVAX.

Financial health

How did Novavax financials performed over time
Novavax's total assets is 48% higher than its total liabilities
The total liabilities has soared by 80% year-on-year and by 16% since the previous quarter
The current ratio has declined by 32% year-on-year and by 6% since the previous quarter
Novavax's equity has surged by 156% YoY but it has decreased by 42% QoQ
Novavax's debt has increased by 38% YoY and by 37% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.